Publications by Prof. van Dongen and colleagues

1: van Brummelen EMJ, Huisman MC, de Wit-van der Veen LJ, Nayak TK, Stokkel MPM,
Mulder ER, Hoekstra OS, Vugts DJ, Van Dongen GAMS, Verheul HM, Evers S, Tessier
JJL, Saro J, Schellens JHM, Menke-van der Houven van Oordt CW. (89)Zr-labeled
CEA-targeted I2L variant immunocytokine in patients with solid tumors:
CEA-mediated tumor accumulation and role of I2L receptor-binding. Oncotarget.
2018 May 15;9(37):24737-24749. doi: 10.18632/oncotarget.25343. eCollection 2018

May 15. PubMed PMID: 29872502; PubMed Central PMCID: PMC5973872.

2: Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, Vugts DJ, Roth C,
Luik AM, Mulder ER, Schuit RC, Boellaard R, Hoekstra OS, van Dongen GA, Verheul
HM. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
Oncotarget. 2015 Oct 6;6(30):30384-93. doi: 10.18632/oncotarget.4672. PubMed

PMID: 26309164; PubMed Central PMCID: PMC4745807.

3: Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts
DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van
Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera
Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G,
Moessner E, Umaña P. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted I2L
variant-based immunocytokine for combination cancer immunotherapy: Overcoming
limitations of aldesleukin and conventional I2L-based immunocytokines.
Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402×.2016.1277306.

eCollection 2017. PubMed PMID: 28405498; PubMed Central PMCID: PMC5384349.

4: Jauw YW, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, van Dongen
GA, Huisman MC. Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker
to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory
Diffuse Large B Cell Lymphoma. PLoS One. 2017 Jan 6;12(1):e0169828. doi:

10.1371/journal.pone.0169828. eCollection 2017. PubMed PMID: 28060891; PubMed

Central PMCID: PMC5218417.

5: Jauw YWS, Huisman MC, Nayak TK, Vugts DJ, Christen R, Naegelen VM, Ruettinger
D, Heil F, Lammertsma AA, Verheul HMW, Hoekstra OS, van Dongen GAMS, Menke-van
der Houven van Oordt CW. Assessment of target-mediated uptake with immuno-PET:
analysis of a phase I clinical trial with an anti-CD44 antibody. EJNMMI Res. 2018
Jan 22;8(1):6. doi: 10.1186/s13550-018-0358-8. PubMed PMID: 29356983; PubMed

Central PMCID: PMC5778091.

6: Vugts DJ, Heuveling DA, Stigter-van Walsum M, Weigand S, Bergstrom M, van
Dongen GA, Nayak TK. Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal
antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical
studies. MAbs. 2014 Mar-Apr;6(2):567-75. doi: 10.4161/mabs.27415. Epub 2013 Dec

9. PubMed PMID: 24492295; PubMed Central PMCID: PMC3984344.

7: Even AJ, Hamming-Vrieze O, van Elmpt W, Winnepenninckx VJ, Heukelom J,
Tesselaar ME, Vogel WV, Hoeben A, Zegers CM, Vugts DJ, van Dongen GA, Bartelink
H, Mottaghy FM, Hoebers F, Lambin P. Quantitative assessment of Zirconium-89
labeled cetuximab using PET/CT imaging in patients with advanced head and neck
cancer: a theragnostic approach. Oncotarget. 2017 Jan 17;8(3):3870-3880. doi:

10.18632/oncotarget.13910. PubMed PMID: 27965472; PubMed Central PMCID:

PMC5354801.

8: Jansen MH, Veldhuijzen van Zanten SEM, van Vuurden DG, Huisman MC, Vugts DJ,
Hoekstra OS, van Dongen GA, Kaspers GL. Molecular Drug Imaging:
(89)Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. J Nucl
Med. 2017 May;58(5):711-716. doi: 10.2967/jnumed.116.180216. Epub 2016 Oct 20.

PubMed PMID: 27765855.

9: Jauw YW, Menke-van der Houven van Oordt CW, Hoekstra OS, Hendrikse NH, Vugts
DJ, Zijlstra JM, Huisman MC, van Dongen GA. Immuno-Positron Emission Tomography
with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn
from Initial Clinical Trials? Front Pharmacol. 2016 May 24;7:131. doi:

10.3389/fphar.2016.00131. eCollection 2016. Review. PubMed PMID: 27252651; PubMed

Central PMCID: PMC4877495.

10: Heuveling DA, de Bree R, Vugts DJ, Huisman MC, Giovannoni L, Hoekstra OS,
Leemans CR, Neri D, van Dongen GA. Phase 0 microdosing PET study using the human
mini antibody F16SIP in head and neck cancer patients. J Nucl Med. 2013
Mar;54(3):397-401. doi: 10.2967/jnumed.112.111310. Epub 2013 Jan 18. PubMed PMID:

23334725.

11: Vugts DJ, van Dongen GA. (89)Zr-labeled compounds for PET imaging guided
personalized therapy. Drug Discov Today Technol. 2011 Summer;8(2-4):e53-61. doi:

10.1016/j.ddtec.2011.12.004. PubMed PMID: 24990263.

12: Van Dongen GA, Huisman MC, Boellaard R, Harry Hendrikse N, Windhorst AD,
Visser GW, Molthoff CF, Vugts DJ. 89Zr-immuno-PET for imaging of long circulating
drugs and disease targets: why, how and when to be applied? Q J Nucl Med Mol
Imaging. 2015 Mar;59(1):18-38. Epub 2014 Dec 17. Review. PubMed PMID: 25517081.

13: Jauw YWS, Heijtel DF, Zijlstra JM, Hoekstra OS, de Vet HCW, Vugts DJ, Verheul
HM, Boellaard R, Zweegman S, van Dongen GAMS, der Houven van Oordt CWM,
Lammertsma AA, Huisman MC. Noise-Induced Variability of Immuno-PET with
Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical
Images. Mol Imaging Biol. 2018 Apr 30. doi: 10.1007/s11307-018-1200-4. [Epub

ahead of print] PubMed PMID: 29713958.

14: Vugts DJ, Visser GW, van Dongen GA. 89Zr-PET radiochemistry in the
development and application of therapeutic monoclonal antibodies and other
biologicals. Curr Top Med Chem. 2013;13(4):446-57. Review. PubMed PMID: 23432007.

15: Makris NE, Boellaard R, van Lingen A, Lammertsma AA, van Dongen GA, Verheul
HM, Menke CW, Huisman MC. PET/CT-derived whole-body and bone marrow dosimetry of
89Zr-cetuximab. J Nucl Med. 2015 Feb;56(2):249-54. doi:

10.2967/jnumed.114.147819. Epub 2015 Jan 22. PubMed PMID: 25613538.

16: Bruijnen S, Tsang-A-Sjoe M, Raterman H, Ramwadhdoebe T, Vugts D, van Dongen
G, Huisman M, Hoekstra O, Tak PP, Voskuyl A, van der Laken C. B-cell imaging with
zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic
response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis
patients. Arthritis Res Ther. 2016 Nov 18;18(1):266. PubMed PMID: 27863504;

PubMed Central PMCID: PMC5116204.

17: Makris NE, Boellaard R, Visser EP, de Jong JR, Vanderlinden B, Wierts R, van
der Veen BJ, Greuter HJ, Vugts DJ, van Dongen GA, Lammertsma AA, Huisman MC.
Multicenter harmonization of 89Zr PET/CT performance. J Nucl Med. 2014
Feb;55(2):264-7. doi: 10.2967/jnumed.113.130112. Epub 2013 Dec 19. PubMed PMID:

24357686.

18: Heuveling DA, van Schie A, Vugts DJ, Hendrikse NH, Yaqub M, Hoekstra OS,
Karagozoglu KH, Leemans CR, van Dongen GA, de Bree R. Pilot study on the
feasibility of PET/CT lymphoscintigraphy with 89Zr-nanocolloidal albumin for
sentinel node identification in oral cancer patients. J Nucl Med. 2013
Apr;54(4):585-9. doi: 10.2967/jnumed.112.115188. Epub 2013 Feb 1. PubMed PMID:

23378643.

19: van Dongen GA, Poot AJ, Vugts DJ. PET imaging with radiolabeled antibodies
and tyrosine kinase inhibitors: immuno-PET and TKI-PET. Tumour Biol. 2012
Jun;33(3):607-15. doi: 10.1007/s13277-012-0316-4. Epub 2012 Jan 21. Review.

PubMed PMID: 22270450; PubMed Central PMCID: PMC3342498.

20: Cohen R, Vugts DJ, Stigter-van Walsum M, Visser GW, van Dongen GA. Inert
coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or
dual-mode fluorescence and PET imaging. Nat Protoc. 2013 May;8(5):1010-8. doi:

10.1038/nprot.2013.054. Epub 2013 Apr 25. PubMed PMID: 23619892.

21: Nagengast WB, de Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H,
Brouwers AH, van Dongen GA, Perk LR, Lub-de Hooge MN. In vivo VEGF imaging with
radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007
Aug;48(8):1313-9. Epub 2007 Jul 13. PubMed PMID: 17631557.

22: Nagengast WB, de Korte MA, Oude Munnink TH, Timmer-Bosscha H, den Dunnen WF,
Hollema H, de Jong JR, Jensen MR, Quadt C, Garcia-Echeverria C, van Dongen GA,
Lub-de Hooge MN, Schröder CP, de Vries EG. 89Zr-bevacizumab PET of early
antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J

Nucl Med. 2010 May;51(5):761-7. doi: 10.2967/jnumed.109.071043. Epub 2010 Apr 15.

PubMed PMID: 20395337.

23: Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, Lambin P.
Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake
assessed with PET. J Nucl Med. 2009 Jan;50(1):123-31. doi:

10.2967/jnumed.108.054312. Epub 2008 Dec 17. PubMed PMID: 19091906.

24: Bahce I, Huisman MC, Verwer EE, Ooijevaar R, Boutkourt F, Vugts DJ, van
Dongen GA, Boellaard R, Smit EF. Pilot study of (89)Zr-bevacizumab positron
emission tomography in patients with advanced non-small cell lung cancer. EJNMMI
Res. 2014 Dec;4(1):35. doi: 10.1186/s13550-014-0035-5. Epub 2014 Aug 2. PubMed

PMID: 26055936; PubMed Central PMCID: PMC4884046.

25: Lubberink M, van Schie A, de Jong HW, van Dongen GA, Teule GJ. Acquisition
settings for PET of 124I administered simultaneously with therapeutic amounts of
131I. J Nucl Med. 2006 Aug;47(8):1375-81. PubMed PMID: 16883019.

26: Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, Bart J, de
Jong JR, de Vries EG, Lub-de Hooge MN. Development and characterization of
clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med. 2009
Jun;50(6):974-81. doi: 10.2967/jnumed.108.060392. Epub 2009 May 14. PubMed PMID:

19443585.

27: Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, van
Dongen GA, Oyen WJ, Boerman OC, Bussink J. PET of hypoxia with 89Zr-labeled
cG250-F(ab’)2 in head and neck tumors. J Nucl Med. 2010 Jul;51(7):1076-83. doi:

10.2967/jnumed.109.073189. Epub 2010 Jun 16. PubMed PMID: 20554724.

28: Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR,
van Dongen GA. (89)Zr as a PET surrogate radioisotope for scouting
biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing
nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med.
2005 Nov;46(11):1898-906. PubMed PMID: 16269605.

29: Postema EJ, Raemaekers JM, Oyen WJ, Boerman OC, Mandigers CM, Goldenberg DM,
van Dongen GA, Corstens FH. Final results of a phase I radioimmunotherapy trial
using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin’s
lymphoma. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3995400S2S. PubMed PMID:
14506199.

30: de Jong A, Mous R, van Dongen GA, Hoekstra OS, Nievelstein RA, de Keizer B.
(89) Zr-rituximab PET/CT to detect neurolymphomatosis. Am J Hematol. 2016
Jun;91(6):649-50. doi: 10.1002/ajh.24328. Epub 2016 Apr 13. PubMed PMID:

26872558.

31: Rizvi SN, Visser OJ, Vosjan MJ, van Lingen A, Hoekstra OS, Zijlstra JM,
Huijgens PC, van Dongen GA, Lubberink M. Biodistribution, radiation dosimetry and
scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell
non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET. Eur J Nucl Med
Mol Imaging. 2012 Mar;39(3):512-20. doi: 10.1007/s00259-011-2008-5. Epub 2012 Jan

5. PubMed PMID: 22218876; PubMed Central PMCID: PMC3276758.

32: Vugts DJ, Klaver C, Sewing C, Poot AJ, Adamzek K, Huegli S, Mari C, Visser
GW, Valverde IE, Gasser G, Mindt TL, van Dongen GA. Comparison of the octadentate
bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate
bifunctional chelator DFO-pPhe-NCS for (89)Zr-immuno-PET. Eur J Nucl Med Mol
Imaging. 2017 Feb;44(2):286-295. doi: 10.1007/s00259-016-3499-x. Epub 2016 Aug

30. PubMed PMID: 27573793; PubMed Central PMCID: PMC5215071.

33: Jansen MH, Lagerweij T, Sewing AC, Vugts DJ, van Vuurden DG, Molthoff CF,
Caretti V, Veringa SJ, Petersen N, Carcaboso AM, Noske DP, Vandertop WP,
Wesseling P, van Dongen GA, Kaspers GJ, Hulleman E. Bevacizumab Targeting Diffuse
Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor
Models. Mol Cancer Ther. 2016 Sep;15(9):2166-74. doi:

10.1158/1535-7163.MC15055T8. Epub 2016 Jun 20. PubMed PMID: 27325687.

34: Maussang D, Verzijl D, van Walsum M, Leurs R, Holl J, Pleskoff O, Michel D,
van Dongen GA, Smit MJ. Human cytomegalovirus-encoded chemokine receptor US28
promotes tumorigenesis. Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13068-73.

Epub 2006 Aug 21. PubMed PMID: 16924106; PubMed Central PMCID: PMC1559754.

35: Verel I, Visser GW, van Dongen GA. The promise of immuno-PET in
radioimmunotherapy. J Nucl Med. 2005 Jan;46 Suppl 1:16471SS. Review. PubMed
PMID: 15653665.

36: Vrouenraets MB, Visser GW, Snow GB, van Dongen GA. Basic principles,
applications in oncology and improved selectivity of photodynamic therapy.
Anticancer Res. 2003 Jan-Feb;23(1B):505-22. Review. PubMed PMID: 12680139.

37: Heuveling DA, Visser GW, Baclayon M, Roos WH, Wuite GJ, Hoekstra OS, Leemans
CR, de Bree R, van Dongen GA. 89Zr-nanocolloidal albumin-based PET/CT
lymphoscintigraphy for sentinel node detection in head and neck cancer:
preclinical results. J Nucl Med. 2011 Oct;52(10):1580-4. doi:

10.2967/jnumed.111.089557. Epub 2011 Sep 2. PubMed PMID: 21890880.

38: Gerretsen M, Visser GW, van Walsum M, Meijer CJ, Snow GB, van Dongen GA.
186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human
head and neck squamous cell carcinoma xenografts. Cancer Res. 1993 Aug
1;53(15):3524-9. PubMed PMID: 8339258.

39: Verel I, Heider KH, Siegmund M, Ostermann E, Patzelt E, Sproll M, Snow GB,
Adolf GR, van Dongen GA. Tumor targeting properties of monoclonal antibodies with
different affinity for target antigen CD44V6 in nude mice bearing head-and-neck
cancer xenografts. Int J Cancer. 2002 May 20;99(3):396-402. PubMed PMID:

11992408.

40: Heuveling DA, Karagozoglu KH, Van Lingen A, Hoekstra OS, Van Dongen GAMS, De
Bree R. Feasibility of intraoperative detection of sentinel lymph nodes with
89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy
gamma probe. EJNMMI Res. 2018 Feb 14;8(1):15. doi: 10.1186/s13550-018-0368-6.

PubMed PMID: 29445878; PubMed Central PMCID: PMC5812956.

41: Vrouenraets MB, Visser GW, Loup C, Meunier B, Stigter M, Oppelaar H, Stewart
FA, Snow GB, van Dongen GA. Targeting of a hydrophilic photosensitizer by use of
internalizing monoclonal antibodies: A new possibility for use in photodynamic
therapy. Int J Cancer. 2000 Oct 1;88(1):108-14. PubMed PMID: 10962447.

42: Vugts DJ, Vervoort A, Stigter-van Walsum M, Visser GW, Robillard MS,
Versteegen RM, Vulders RC, Herscheid JK, van Dongen GA. Synthesis of phosphine
and antibody-azide probes for in vivo Staudinger ligation in a pretargeted
imaging and therapy approach. Bioconjug Chem. 2011 Oct 19;22(10):2072-81. doi:

10.1021/bc200298v. Epub 2011 Sep 9. PubMed PMID: 21854058.

43: Vrouenraets MB, Visser GW, Stigter M, Oppelaar H, Snow GB, van Dongen GA.
Comparison of aluminium (III) phthalocyanine tetrasulfonate- and
meta-tetrahydroxyphenylchlorin-monoclonal antibody conjugates for their efficacy
in photodynamic therapy in vitro. Int J Cancer. 2002 Apr 10;98(5):793-8. PubMed

PMID: 11920653.

44: Vrouenraets MB, Visser GW, Stewart FA, Stigter M, Oppelaar H, Postmus PE,
Snow GB, van Dongen GA. Development of meta-tetrahydroxyphenylchlorin-monoclonal
antibody conjugates for photoimmunotherapy. Cancer Res. 1999 Apr 1;59(7):1505-13.

PubMed PMID: 10197621.

45: Slobbe P, Windhorst AD, Stigter-van Walsum M, Smit EF, Niessen HG, Solca F,
Stehle G, van Dongen GA, Poot AJ. A comparative PET imaging study with the
reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and
[(18)F]afatinib in lung cancer-bearing mice. EJNMMI Res. 2015 Mar 20;5:14. doi:

10.1186/s13550-015-0088-0. eCollection 2015. PubMed PMID: 25853020; PubMed

Central PMCID: PMC4385286.

46: Slobbe P, Windhorst AD, Stigter-van Walsum M, Schuit RC, Smit EF, Niessen HG,
Solca F, Stehle G, van Dongen GA, Poot AJ. Development of ["[18f]" not found]afatinib as new
TKI-PET tracer for EGFR positive tumors. Nucl Med Biol. 2014 Oct;41(9):749-57.

doi: 10.1016/j.nucmedbio.2014.06.005. Epub 2014 Jun 25. PubMed PMID: 25066021.

47: Poot AJ, van der Wildt B, Stigter-van Walsum M, Rongen M, Schuit RC,
Hendrikse NH, Eriksson J, van Dongen GA, Windhorst AD. [¹¹C]Sorafenib:
radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET
tracer. Nucl Med Biol. 2013 May;40(4):488-97. doi:

10.1016/j.nucmedbio.2013.02.002. Epub 2013 Mar 20. PubMed PMID: 23522977.

48: Perk LR, Vosjan MJ, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA.
p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile
radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):250-9. doi: 10.1007/s00259-009-1263-1.

Epub 2009 Sep 18. PubMed PMID: 19763566; PubMed Central PMCID: PMC2816257.

49: Slobbe P, Poot AJ, Haumann R, Schuit RC, Windhorst AD, van Dongen GA. Two
anti-angiogenic TKI-PET tracers, [(11)C]axitinib and [(11)C]nintedanib:
Radiosynthesis, in vivo metabolism and initial biodistribution studies in
rodents. Nucl Med Biol. 2016 Oct;43(10):612-24. doi:

10.1016/j.nucmedbio.2016.07.003. Epub 2016 Jul 14. PubMed PMID: 27497236.

50: Quak JJ, Van Dongen G, Brakkee JG, Hayashida DJ, Balm AJ, Snow GB, Meijer CJ.
Production of a monoclonal antibody (K 931) to a squamous cell carcinoma
associated antigen identified as the 17-1A antigen. Hybridoma. 1990
Aug;9(4):377-87. PubMed PMID: 2210778.

51: de Nooij-van Dalen AG, van Dongen GA, Smeets SJ, Nieuwenhuis EJ, Stigter-van
Walsum M, Snow GB, Brakenhoff RH. Characterization of the human 6Ly antigens,
the newly annotated member 6LyK included, as molecular markers for head-and-neck
squamous cell carcinoma. Int J Cancer. 2003 Mar 1;103(6):768-74. PubMed PMID:

12516096.

52: van Dongen G, Braakhuis BJ, Bagnay M, Leyva A, Snow GB. Activity of
differentiation-inducing agents and conventional drugs in head and neck cancer
xenografts. Acta Otolaryngol. 1988 May-Jun;105(5-6):488-93. PubMed PMID: 2456664.

53: Visser OJ, Perk LR, Zijlstra JM, van Dongen GA, Huijgens PC, van de
Loosdrecht AA. Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in
relapsed, refractory and transformed disease. BioDrugs. 2006;20(4):201-7. Review.

PubMed PMID: 16831019.

54: Roovers RC, van Dongen GA, van Bergen en Henegouwen PM. Nanobodies in
therapeutic applications. Curr Opin Mol Ther. 2007 Aug;9(4):327-35. Review.

PubMed PMID: 17694445.

55: Gaillard PJ, Appeldoorn CC, Dorland R, van Kregten J, Manca F, Vugts DJ,
Windhorst B, van Dongen GA, de Vries HE, Maussang D, van Tellingen O.
Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of
glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One. 2014 Jan
8;9(1):e82331. doi: 10.1371/journal.pone.0082331. eCollection 2014. PubMed PMID:

24416140; PubMed Central PMCID: PMC3885379.

56: Branderhorst W, Blezer EL, Houtkamp M, Ramakers RM, van den Brakel JH,
Witteveen H, van der Have F, Gratama van Andel HA, Vastenhouw B, Wu C, Walsum MS,
van Dongen GA, Viergever MA, Bleeker WK, Beekman FJ. Three-dimensional histologic
validation of high-resolution SPECT of antibody distributions within xenografts.
J Nucl Med. 2014 May;55(5):830-7. doi: 10.2967/jnumed.113.125401. Epub 2014 Mar

31. PubMed PMID: 24686779.

57: Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree
R, Lang M, Munzert G, van Dongen GA, Oyen WJ. Dosimetric analysis of
radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck
cancer. J Nucl Med. 2003 Oct;44(10):1690-9. PubMed PMID: 14530488.

58: Muns JA, Montserrat V, Houthoff HJ, Codée-van der Schilden K, Zwaagstra O,
Sijbrandi NJ, Merkul E, van Dongen GAMS. In Vivo Characterization of
Platinum(II)-Based Linker Technology for the Development of Antibody-Drug
Conjugates: Taking Advantage of Dual Labeling with (195m)Pt and (89)Zr. J Nucl
Med. 2018 Jul;59(7):1146-1151. doi: 10.2967/jnumed.117.206672. Epub 2018 Mar 1.

PubMed PMID: 29496986.

59: Colnot DR, Quak JJ, Roos JC, de Bree R, Wilhelm AJ, Snow GB, van Dongen GA.
Radioimmunotherapy in patients with head and neck squamous cell carcinoma:
initial experience. Head Neck. 2001 Jul;23(7):559-65. PubMed PMID: 11400244.

60: Vosjan MJ, Perk LR, Roovers RC, Visser GW, Stigter-van Walsum M, van Bergen
En Henegouwen PM, van Dongen GA. Facile labelling of an anti-epidermal growth
factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for
immuno-PET. Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):753-63. doi:

10.1007/s00259-010-1700-1. Epub 2011 Jan 6. PubMed PMID: 21210114; PubMed Central

PMCID: PMC3053459.

61: Slobbe P, Windhorst AD, Adamzek K, Bolijn M, Schuit RC, Heideman DAM, van
Dongen GAMS, Poot AJ. Development of ["[11c]" not found]vemurafenib employing a carbon-11
carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma
tumor xenografts. Oncotarget. 2017 Jun 13;8(24):38337-38350. doi:

10.18632/oncotarget.16321. PubMed PMID: 28418885; PubMed Central PMCID:

PMC5503536.

62: Cohen R, Vugts DJ, Visser GW, Stigter-van Walsum M, Bolijn M, Spiga M,
Lazzari P, Shankar S, Sani M, Zanda M, van Dongen GA. Development of novel ADCs:
conjugation of tubulysin analogues to trastuzumab monitored by dual
radiolabeling. Cancer Res. 2014 Oct 15;74(20):5700-10. doi:

10.1158/0008-5472.CA14114N1. Epub 2014 Aug 21. PubMed PMID: 25145670.

63: Brouwers A, Verel I, Van Eerd J, Visser G, Steffens M, Oosterwijk E, Corstens
F, Oyen W, Van Dongen G, Boerman O. PET radioimmunoscintigraphy of renal cell
cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother
Radiopharm. 2004 Apr;19(2):155-63. PubMed PMID: 15186595.

64: Tijink BM, Perk LR, Budde M, Stigter-van Walsum M, Visser GW, Kloet RW,
Dinkelborg LM, Leemans CR, Neri D, van Dongen GA. (124)I-L19-SIP for immuno-PET
imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy.
Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1235-44. doi:

10.1007/s00259-009-1096-y. Epub 2009 Mar 4. PubMed PMID: 19259661; PubMed Central

PMCID: PMC2709218.

65: Verel I, Visser GW, Vosjan MJ, Finn R, Boellaard R, van Dongen GA.
High-quality 124I-labelled monoclonal antibodies for use as PET scouting agents
prior to 131I-radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2004
Dec;31(12):1645-52. Epub 2004 Jul 31. PubMed PMID: 15290121.

66: de Bree R, Roos JC, Quak JJ, den Hollander W, van den Brekel MW, van der Wal
JE, Tobi H, Snow GB, van Dongen GA. Clinical imaging of head and neck cancer with
technetium-99m-labeled monoclonal antibody E48 IgG or F(ab’)2. J Nucl Med. 1994

May;35(5):775-83. PubMed PMID: 8176458.

67: Wiegant FA, van Bergen en Henegouwen PM, van Dongen G, Linnemans WA.
Stress-induced thermotolerance of the cytoskeleton of mouse neuroblastoma N2A
cells and rat Reuber H35 hepatoma cells. Cancer Res. 1987 Mar 15;47(6):1674-80.

PubMed PMID: 3815363.

68: de Bree R, Roos JC, Quak JJ, den Hollander W, Snow GB, van Dongen GA.
Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal
antibody U36 in patients with head and neck cancer. Clin Cancer Res. 1995
Jun;1(6):591-8. PubMed PMID: 9816020.

69: Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR,
van Dongen GA, Schröder CP, Lub-de Hooge MN, de Vries EG. Biodistribution of
89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with
metastatic breast cancer. Clin Pharmacol Ther. 2010 May;87(5):586-92. doi:

10.1038/clpt.2010.12. Epub 2010 Mar 31. PubMed PMID: 20357763.

70: van Bergen en Henegouwen PM, Jordi WJ, van Dongen G, Ramaekers FC, Amesz H,
Linnemans WA. Studies on a possible relationship between alterations in the
cytoskeleton and induction of heat shock protein synthesis in mammalian cells.
Int J Hyperthermia. 1985 Jan-Mar;1(1):69-83. PubMed PMID: 2426373.

71: Perk LR, Visser OJ, Stigter-van Walsum M, Vosjan MJ, Visser GW, Zijlstra JM,
Huijgens PC, van Dongen GA. Preparation and evaluation of (89)Zr-Zevalin for
monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.
Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45. Epub 2006 Jul 11. PubMed

PMID: 16832633.

72: van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M,
Dingemans AM, Lalisang R, Brans B, Windhorst B, van Dongen GA, Kolb H, Zhang J,
De Ruysscher D, Lambin P. PET imaging of hypoxia using ["[18f]" not found]HX4: a phase I trial.
Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1663-8. doi:

10.1007/s00259-010-1437-x. Epub 2010 Apr 6. PubMed PMID: 20369236.

73: Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA,
Dubois L, Lambin P. A comparative study of the hypoxia PET tracers [¹⁸F]HX4,
[¹⁸F]FAZA, and [¹⁸F]FMISO in a preclinical tumor model. Int J Radiat Oncol Biol
Phys. 2015 Feb 1;91(2):351-9. doi: 10.1016/j.ijrobp.2014.09.045. Epub 2014 Dec 6.

PubMed PMID: 25491505.

74: Bahce I, Yaqub M, Smit EF, Lammertsma AA, van Dongen GA, Hendrikse NH.
Personalizing NSCLC therapy by characterizing tumors using TKI-PET and
immuno-PET. Lung Cancer. 2017 May;107:1-13. doi: 10.1016/j.lungcan.2016.05.025.

Epub 2016 May 31. Review. PubMed PMID: 27319335.

75: Slobbe P, Poot AJ, Windhorst AD, van Dongen GA. PET imaging with
small-molecule tyrosine kinase inhibitors: TKI-PET. Drug Discov Today. 2012
Nov;17(21-22):1175-87. doi: 10.1016/j.drudis.2012.06.016. Epub 2012 Jul 2.

Review. PubMed PMID: 22766374.

76: van Dongen GA, Visser GW, Vrouenraets MB. Photosensitizer-antibody conjugates
for detection and therapy of cancer. Adv Drug Deliv Rev. 2004 Jan 13;56(1):31-52.

Review. PubMed PMID: 14706444.

77: Gerretsen M, Visser GW, Brakenhoff RH, van Walsum M, Snow GB, van Dongen GA.
Complete ablation of small squamous cell carcinoma xenografts with 186Re-labeled
monoclonal antibody E48. Cell Biophys. 1994;24-25:135-42. PubMed PMID: 7736517.

78: Cohen R, Stammes MA, de Roos IH, Stigter-van Walsum M, Visser GW, van Dongen
GA. Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical
imaging of tumor targets. EJNMMI Res. 2011 Dec 1;1(1):31. doi:

10.1186/2191-219131X. PubMed PMID: 22214225; PubMed Central PMCID: PMC3250998.

79: Colnot DR, Nieuwenhuis EJ, Kuik DJ, Leemans CR, Dijkstra J, Snow GB, van
Dongen GA, Brakenhoff RH. Clinical significance of micrometastatic cells detected
by E48(6LyD) reverse transcription-polymerase chain reaction in bone marrow of
head and neck cancer patients. Clin Cancer Res. 2004 Dec 1;10(23):7827-33. PubMed

PMID: 15585614.

80: Poot AJ, Slobbe P, Hendrikse NH, Windhorst AD, van Dongen GA. Imaging of
TKI-target interactions for personalized cancer therapy. Clin Pharmacol Ther.
2013 Mar;93(3):239-41. doi: 10.1038/clpt.2012.242. Epub 2012 Dec 12. PubMed PMID:

23340475.

81: Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, van Dongen GA.
Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET
imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.
Nat Protoc. 2010 Apr;5(4):739-43. doi: 10.1038/nprot.2010.13. Epub 2010 Mar 25.

PubMed PMID: 20360768.

82: Oliveira S, Cohen R, Walsum MS, van Dongen GA, Elias SG, van Diest PJ, Mali
W, van Bergen En Henegouwen PM. A novel method to quantify IRDye800CW fluorescent
antibody probes ex vivo in tissue distribution studies. EJNMMI Res. 2012 Sep
25;2(1):50. doi: 10.1186/2191-219250X. PubMed PMID: 23009555; PubMed Central

PMCID: PMC3519726.

83: van Dongen G, Zoutewelle G, van Rijn J, van Wijk R. Cell killing and
sensitization to heat shock by hypothermic incubation of asynchronous and
synchronized mouse neuroblastoma cells. Cancer Res. 1985 Sep;45(9):4132-7. PubMed

PMID: 4028005.

84: van Dongen G, van Wijk R. Evidence for a role of heat-shock proteins in
proliferation after heat treatment of synchronized mouse neuroblastoma cells.
Radiat Res. 1988 Feb;113(2):252-67. PubMed PMID: 3340732.

85: van Dongen G, van Wijk R. Effect of serum on heat response of synchronized
mouse neuroblastoma cells: protection of cell cycle progression, protein
synthesis and survival. Int J Radiat Biol Relat Stud Phys Chem Med. 1986
Jul;50(1):77-91. PubMed PMID: 3487527.

86: van Dongen G, van de Zande L, Schamhart D, Van Wijk R. Comparative studies on
the heat-induced thermotolerance of protein synthesis and cell division in
synchronized mouse neuroblastoma cells. Int J Radiat Biol Relat Stud Phys Chem
Med. 1984 Dec;46(6):759-69. PubMed PMID: 6396262.

87: van Dongen G, Geilenkirchen WL, van Rijn J, van Wijk R. Increase of
thermoresistance after growth stimulation of resting Reuber H35 hepatoma cells.
Alteration of nuclear characteristics, non-histone chromosomal protein
phosphorylation and basal heat shock protein synthesis. Exp Cell Res. 1986
Oct;166(2):427-41. PubMed PMID: 3743664.

88: Quak J, van Dongen G. Current perspectives in the use of monoclonal
antibodies for detection and treatment of head and neck tumors. Eur Arch
Otorhinolaryngol. 1994;251(1):1-5. Review. PubMed PMID: 8179860.

89: Eshel R, Zanin A, Sagi-Assif O, Meshel T, Smorodinsky NI, Dwir O, Alon R,
Brakenhoff R, van Dongen G, Witz IP. The GPI-linked 6Ly antigen E48 regulates
expression levels of the FX enzyme and of E-selectin ligands on head and neck
squamous carcinoma cells. J Biol Chem. 2000 Apr 28;275(17):12833-40. PubMed PMID:

10777581.

90: van Hal NL, van Dongen GA, Stigter-van Walsum M, Snow GB, Brakenhoff RH.
Characterization of CD44v6 isoforms in head-and-neck squamous-cell carcinoma. Int
J Cancer. 1999 Sep 9;82(6):837-45. PubMed PMID: 10446451.

91: Brakenhoff RH, Stroomer JG, ten Brink C, de Bree R, Weima SM, Snow GB, van
Dongen GA. Sensitive detection of squamous cells in bone marrow and blood of head
and neck cancer patients by E48 reverse transcriptase-polymerase chain reaction.
Clin Cancer Res. 1999 Apr;5(4):725-32. PubMed PMID: 10213205.

92: Van Hal NL, Van Dongen GA, Ten Brink CB, Heider KH, Rech-Weichselbraun I,
Snow GB, Brakenhoff RH. Evaluation of soluble CD44v6 as a potential serum marker
for head and neck squamous cell carcinoma. Clin Cancer Res. 1999
Nov;5(11):3534-41. PubMed PMID: 10589769.

93: Brakenhoff RH, Gerretsen M, Knippels EM, van Dijk M, van Essen H, Weghuis DO,
Sinke RJ, Snow GB, van Dongen GA. The human E48 antigen, highly homologous to the
murine 6Ly antigen ThB, is a GPI-anchored molecule apparently involved in
keratinocyte cell-cell adhesion. J Cell Biol. 1995 Jun;129(6):1677-89. PubMed

PMID: 7790363; PubMed Central PMCID: PMC2291189.

94: van Gog FB, Brakenhoff RH, Snow GB, van Dongen GA. Rapid elimination of
mouse/human chimeric monoclonal antibodies in nude mice. Cancer Immunol
Immunother. 1997 Apr;44(2):103-11. PubMed PMID: 9177472.

95: van Dongen GA, Brakenhoff RM, ten Brink CT, van Gog FB, de Bree R, Quak JJ,
Snow GB. Squamous cell carcinoma-associated antigens used in novel strategies for
the detection and treatment of minimal residual head and neck cancer. Anticancer
Res. 1996 Jul-Aug;16(4C):2409-13. Review. PubMed PMID: 8816843.

96: Van Hal NL, Van Dongen GA, Ten Brink CB, Herron JN, Snow GB, Brakenhoff RH.
Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitope. Cancer
Immunol Immunother. 1997 Oct;45(2):88-92. PubMed PMID: 9390199.

97: Vandongen G, Brakenhoff R, Debree R, Gerretsen M, Quak J, Snow G. Progress in
radioimmunotherapy of head and neck-cancer (review). Oncol Rep. 1994
Jan;1(1):259-64. PubMed PMID: 21607350.

98: van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET:
a navigator in monoclonal antibody development and applications. Oncologist. 2007
Dec;12(12):1379-89. doi: 10.1634/theoncologist.12-12-1379. Review. PubMed PMID:

18165614.

99: Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens
PC, Snow GB, van Dongen GA. Phase I therapy study of 186Re-labeled chimeric
monoclonal antibody U36 in patients with squamous cell carcinoma of the head and
neck. J Nucl Med. 2000 Dec;41(12):1999-2010. PubMed PMID: 11138685.

100: Brakenhoff RH, van Gog FB, Looney JE, van Walsum M, Snow GB, van Dongen GA.
Construction and characterization of the chimeric monoclonal antibody E48 for
therapy of head and neck cancer. Cancer Immunol Immunother. 1995
Mar;40(3):191-200. PubMed PMID: 7728778.

101: van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA.
Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for
the treatment of residual head and neck cancer. Int J Cancer. 1998 Jul
3;77(1):13-8. PubMed PMID: 9639387.

102: Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P,
Vanderlinden B, van Dongen GA, Everaert H, Vaes M, Bron D. Tumour targeting and
radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell
lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with
unlabelled rituximab. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1304-14. doi:

10.1007/s00259-015-3025-6. Epub 2015 Mar 20. PubMed PMID: 25792453; PubMed

Central PMCID: PMC4480335.

103: Dubois LJ, Lieuwes NG, Janssen MH, Peeters WJ, Windhorst AD, Walsh JC, Kolb
HC, Ollers MC, Bussink J, van Dongen GA, van der Kogel A, Lambin P. Preclinical
evaluation and validation of ["[18f]" not found]HX4, a promising hypoxia marker for PET
imaging. Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14620-5. doi:

10.1073/pnas.1102526108. Epub 2011 Aug 23. PubMed PMID: 21873245; PubMed Central

PMCID: PMC3167561.

104: van Dongen GA, Leverstein H, Roos JC, Quak JJ, van den Brekel MW, van Lingen
A, Martens HJ, Castelijns JA, Visser GW, Meijer CJ, et al.
Radioimmunoscintigraphy of head and neck cancer using 99mTc-labeled monoclonal
antibody E48 F(ab’)2. Cancer Res. 1992 May 1;52(9):2569-74. PubMed PMID: 1568225.

105: Sung MW, Johnson JT, Van Dongen G, Whiteside TL. Protective effects of
interferon-gamma on squamous-cell carcinoma of head and neck targets in
antibody-dependent cellular cytotoxicity mediated by human natural killer cells.
Int J Cancer. 1996 May 3;66(3):393-9. PubMed PMID: 8621263.

106: van Gog FB, Visser GW, Klok R, van der Schors R, Snow GB, van Dongen GA.
Monoclonal antibodies labeled with rhenium-186 using the MAG3 chelate:
relationship between the number of chelated groups and biodistribution
characteristics. J Nucl Med. 1996 Feb;37(2):352-62. PubMed PMID: 8667076.

107: Visser GW, Klok RP, Gebbinck JW, ter Linden T, van Dongen GA, Molthoff CF.
Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large
reaction volume and temporarily coating the antibody with IODO-GEN. J Nucl Med.
2001 Mar;42(3):509-19. PubMed PMID: 11337531.

108: Colnot DR, Ossenkoppele GJ, Roos JC, Quak JJ, de Bree R, Börjesson PK,
Huijgens PC, Snow GB, van Dongen GA. Reinfusion of unprocessed, granulocyte
colony-stimulating factor-stimulated whole blood allows dose escalation of
186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I
dose escalation study. Clin Cancer Res. 2002 Nov;8(11):3401-6. PubMed PMID:

12429627.

109: de Bree R, Roos JC, Plaizier MA, Quak JJ, van Kamp GJ, den Hollander W, Snow
GB, van Dongen GA. Selection of monoclonal antibody E48 IgG or U36 IgG for
adjuvant radioimmunotherapy in head and neck cancer patients. Br J Cancer.
1997;75(7):1049-60. PubMed PMID: 9083342; PubMed Central PMCID: PMC2222739.

110: Oliveira S, van Dongen GA, Stigter-van Walsum M, Roovers RC, Stam JC, Mali
W, van Diest PJ, van Bergen en Henegouwen PM. Rapid visualization of human tumor
xenografts through optical imaging with a near-infrared fluorescent
anti-epidermal growth factor receptor nanobody. Mol Imaging. 2012
Feb;11(1):33-46. PubMed PMID: 22418026.

111: Sung MW, Yasumura S, Johnson JT, Van Dongen GA, Whiteside TL. Natural killer
(NK) cells as effectors of antibody-dependent cytotoxicity with chimeric
antibodies reactive with human squamous-cell carcinomas of the head and neck. Int
J Cancer. 1995 Jun 9;61(6):864-72. PubMed PMID: 7790123.

112: de Bree R, Kuik DJ, Quak JJ, Roos JC, van den Brekel MW, Castelijns JA, van
Wagtendonk FW, Greuter H, Snow GB, van Dongen GA. The impact of tumour volume and
other characteristics on uptake of radiolabelled monoclonal antibodies in tumour
tissue of head and neck cancer patients. Eur J Nucl Med. 1998 Nov;25(11):1562-5.

PubMed PMID: 9799354.

113: Zheng KH, van der Valk FM, Smits LP, Sandberg M, Dasseux JL, Baron R,
Barbaras R, Keyserling C, Coolen BF, Nederveen AJ, Verberne HJ, Nell TE, Vugts
DJ, Duivenvoorden R, Fayad ZA, Mulder WJM, van Dongen GAMS, Stroes ESG. HDL
mimetic CE001R targets atherosclerotic plaques in patients. Atherosclerosis.
2016 Aug;251:381-388. doi: 10.1016/j.atherosclerosis.2016.05.038. Epub 2016 May

27. PubMed PMID: 27263077.

114: De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GA.
Clinical screening of monoclonal antibodies 323/A3, cS25F and K928 for
suitability of targetting tumours in the upper aerodigestive and respiratory
tract. Nucl Med Commun. 1994 Aug;15(8):613-27. PubMed PMID: 7970443.

115: Gripp FM, Quak J, Leverstein H, Schrijvers A, Gerretsen M, Brakenhoff R, Van
Dongen G, Snow GB, Rapoport A. Monoclonal antibodies for diagnosis and therapy of
squamous cell carcinoma of the head and neck. Sao Paulo Med J. 1994
Jul-Sep;112(3):612-21. Review. PubMed PMID: 7638523.

116: Visser OJ, Zijlstra JM, van Dongen GA, Huijgens PC. [Radio-immunotherapy for
B-cell non-Hodgkin lymphoma]. Ned Tijdschr Geneeskd. 2005 Oct 15;149(42):2324-8.

Review. Dutch. PubMed PMID: 16261710.

117: Van Hal NL, Van Dongen GA, Rood-Knippels EM, Van Der Valk P, Snow GB,
Brakenhoff RH. Monoclonal antibody U36, a suitable candidate for clinical
immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int J
Cancer. 1996 Nov 15;68(4):520-7. PubMed PMID: 8945625.

118: Gerretsen M, Quak JJ, Suh JS, van Walsum M, Meijer CJ, Snow GB, van Dongen
GA. Superior localisation and imaging of radiolabelled monoclonal antibody E48
F(ab’)2 fragment in xenografts of human squamous cell carcinoma of the head and
neck and of the vulva as compared to monoclonal antibody E48 IgG. Br J Cancer.
1991 Jan;63(1):37-44. PubMed PMID: 1989663; PubMed Central PMCID: PMC1971635.

119: Colnot DR, Wilhelm AJ, Cloos J, Roos JC, de Bree R, Quak JJ, Snow GB, van
Dongen GA. Evaluation of limited blood sampling in a preceding 99mTc-labeled
diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb
U36 radioimmunotherapy. J Nucl Med. 2001 Sep;42(9):1364-7. PubMed PMID: 11535726.

120: Börjesson PK, Jauw YW, de Bree R, Roos JC, Castelijns JA, Leemans CR, van
Dongen GA, Boellaard R. Radiation dosimetry of 89Zr-labeled chimeric monoclonal
antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med.
2009 Nov;50(11):1828-36. doi: 10.2967/jnumed.109.065862. Epub 2009 Oct 16. PubMed

PMID: 19837762.

121: Visser GW, Gerretsen M, Herscheid JD, Snow GB, van Dongen G. Labeling of
monoclonal antibodies with rhenium-186 using the MAG3 chelate for
radioimmunotherapy of cancer: a technical protocol. J Nucl Med. 1993
Nov;34(11):1953-63. PubMed PMID: 8229241.

122: Nestor M, Ekberg T, Dring J, van Dongen GA, Wester K, Tolmachev V, Anniko M.
Quantification of CD44v6 and EGFR expression in head and neck squamous cell
carcinomas using a single-dose radioimmunoassay. Tumour Biol. 2007;28(5):253-63.

Epub 2007 Nov 9. PubMed PMID: 17992053.

123: van Dongen GA, Snow GB. Prospects for future studies in head and neck
cancer. Eur J Surg Oncol. 1997 Dec;23(6):486-91. Review. PubMed PMID: 9484916.

124: Nestor M, Persson M, Cheng J, Tolmachev V, van Dongen G, Anniko M, Kairemo
K. Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a
closo-dodecaborate-containing linker. Comparison with other radioiodination
methods. Bioconjug Chem. 2003 Jul-Aug;14(4):805-10. PubMed PMID: 12862434.

125: Stillebroer AB, Franssen GM, Mulders PF, Oyen WJ, van Dongen GA, Laverman P,
Oosterwijk E, Boerman OC. ImmunoPET imaging of renal cell carcinoma with (124)I-
and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Cancer Biother
Radiopharm. 2013 Sep;28(7):510-5. doi: 10.1089/cbr.2013.1487. Epub 2013 May 22.

PubMed PMID: 23697926; PubMed Central PMCID: PMC3741422.

126: Kievit E, van Gog FB, Schlüper HM, van Dongen GA, Pinedo HM, Boven E.
["[186re]" not found]-labeled mouse and chimeric monoclonal antibody 323/A3: a comparison of
the efficacy in experimental human ovarian cancer. Nucl Med Biol. 1998
Jan;25(1):37-45. PubMed PMID: 9466360.

127: Quak JJ, Gerretsen M, Schrijvers AH, Meijer CJ, van Dongen GA, Snow GB.
Detection of squamous cell carcinoma xenografts in nude mice by radiolabeled
monoclonal antibody E48. Arch Otolaryngol Head Neck Surg. 1991

Nov;117(11):1287-91. PubMed PMID: 1747235.

128: El-Emir E, Dearling JL, Huhalov A, Robson MP, Boxer G, Neri D, van Dongen
GA, Trachsel E, Begent RH, Pedley RB. Characterisation and radioimmunotherapy of
L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin,
in colorectal tumour models. Br J Cancer. 2007 Jun 18;96(12):1862-70. Epub 2007

May 22. PubMed PMID: 17519905; PubMed Central PMCID: PMC2359968.

129: Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, van
Dongen GA. MAb U36, a novel monoclonal antibody successful in immunotargeting of
squamous cell carcinoma of the head and neck. Cancer Res. 1993 Sep
15;53(18):4383-90. PubMed PMID: 8364934.

130: van Gog FB, Visser GW, Gowrising RW, Snow GB, van Dongen GA. Synthesis and
evaluation of 99mTc/99Tc-MAG3-biotin conjugates for antibody pretargeting
strategies. Nucl Med Biol. 1998 Oct;25(7):611-9. PubMed PMID: 9804042.

131: Gerretsen M, Schrijvers AH, van Walsum M, Braakhuis BJ, Quak JJ, Meijer CJ,
Snow GB, van Dongen GA. Radioimmunotherapy of human head and neck squamous cell
carcinoma xenografts with 131I-labelled monoclonal antibody E48 IgG. Br J Cancer.
1992 Sep;66(3):496-502. PubMed PMID: 1520586; PubMed Central PMCID: PMC1977958.

132: Nestor M, Persson M, van Dongen GA, Jensen HJ, Lundqvist H, Anniko M,
Tolmachev V. In vitro evaluation of the astatinated chimeric monoclonal antibody
U36, a potential candidate for treatment of head and neck squamous cell
carcinoma. Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1296-304. Epub 2005 Jul

19. PubMed PMID: 16028065.

133: van Dongen GA, Braakhuis BJ, Leyva A, Hendriks HR, Kipp BB, Bagnay M, Snow
GB. Anti-tumor and differentiation-inducing activity of N,N-dimethylformamide
(DMF) in head-and-neck cancer xenografts. Int J Cancer. 1989 Feb 15;43(2):285-92.

PubMed PMID: 2465278.

134: van Dongen GA, Ussi AE, de Man FH, Migliaccio G. EATRIS, a European
initiative to boost translational biomedical research. Am J Nucl Med Mol Imaging.
2013;3(2):166-74. Epub 2013 Mar 8. PubMed PMID: 23526583; PubMed Central PMCID:

PMC3601476.

135: van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding
light on clinical antibody therapy. Cancer Biother Radiopharm. 2010
Aug;25(4):375-85. doi: 10.1089/cbr.2010.0812. Review. PubMed PMID: 20707716.

136: Schrijvers AH, Gerretsen M, Fritz JM, van Walsum M, Quak JJ, Snow GB, van
Dongen GA. Evidence for a role of the monoclonal antibody E48 defined antigen in
cell-cell adhesion in squamous epithelia and head and neck squamous cell
carcinoma. Exp Cell Res. 1991 Oct;196(2):264-9. PubMed PMID: 1893937.

137: Sung MW, Nagashima S, Johnson JT, Van Dongen GA, Whiteside TL. The role of
apoptosis in antibody-dependent cell-mediated cytotoxicity against monolayers of
human squamous cell carcinoma of the head and neck targets. Cell Immunol. 1996
Jul 10;171(1):20-9. PubMed PMID: 8660833.

138: Brown DH, Braakhuis BJ, Van Dongen GA, Snow GB. Comparative study of the
sensitivity of head and neck cell lines to methotrexate (MTX) and the analog
10-ethyl, 10-deazaaminopterin (10-EdAM). Otolaryngol Head Neck Surg. 1990
Jan;102(1):20-5. PubMed PMID: 2106113.

139: Kievit E, van Gog FB, Schlüper HM, van Dongen GA, Pinedo HM, Boven E.
Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3
labeled with either 131I or 186Re in human ovarian cancer xenografts. Int J
Radiat Oncol Biol Phys. 1997 Jul 1;38(4):813-23. PubMed PMID: 9240651.

140: van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GB, van Dongen GA. High
dose rhenium-186-labeling of monoclonal antibodies for clinical application:
pitfalls and solutions. Cancer. 1997 Dec 15;80(12 Suppl):2360-70. PubMed PMID:

9406684.

141: Braakhuis BJ, van Dongen GA, Peters GJ, van Walsum M, Snow GB. Antitumor
activity of brequinar sodium (Dup-785) against human head and neck squamous cell
carcinoma xenografts. Cancer Lett. 1990 Feb;49(2):133-7. PubMed PMID: 2306706.

142: Zätterström UK, Braakhuis BJ, Wennerberg J, van Dongen GA, Attewell R, Nauta
JJ, Laarman DA, Ask A. Growth of xenografted squamous cell carcinoma of the head
and neck—possible correlation with patient survival. APMIS. 1992
Nov;100(11):976-80. PubMed PMID: 1472366.

143: Braakhuis BJ, van Dongen GA, Bagnay M, van Walsum M, Snow GB. Preclinical
chemotherapy on human head and neck cancer xenografts grown in athymic nude mice.
Head Neck. 1989 Nov-Dec;11(6):511-5. PubMed PMID: 2584006.

144: Quak JJ, Schrijvers HG, Brakkee JG, Davis HD, Scheper RJ, Meijer CJ, Snow
GB, Van Dongen GA. Expression and characterization of two differentiation
antigens in human stratified squamous epithelia and carcinomas. Int J Cancer.
1992 Feb 20;50(4):507-13. PubMed PMID: 1537614.

145: Waalboer DC, Muns JA, Sijbrandi NJ, Schasfoort RB, Haselberg R, Somsen GW,
Houthoff HJ, van Dongen GA. Platinum(II) as bifunctional linker in antibody-drug
conjugate formation: coupling of a 4-nitrobenzo-2-oxa-1,3-diazole fluorophore to
trastuzumab as a model. ChemMedChem. 2015 May;10(5):797-803. doi:

10.1002/cmdc.201402496. Epub 2015 Mar 25. PubMed PMID: 25809281.

146: Maussang D, Langemeijer E, Fitzsimons CP, Stigter-van Walsum M, Dijkman R,
Borg MK, Slinger E, Schreiber A, Michel D, Tensen CP, van Dongen GA, Leurs R,
Smit MJ. The human cytomegalovirus-encoded chemokine receptor US28 promotes
angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res. 2009 Apr

1;69(7):2861-9. doi: 10.1158/0008-5472.CA08248N7. Epub 2009 Mar 24. PubMed

PMID: 19318580.

147: Quak JJ, van Dongen G, Koken MA, Brakkee JG, Scheper RJ, Balm AJ, de Jong L,
Snow GB, Meijer CJ. Identification of a 43-kDa nuclear antigen associated with
proliferation by monoclonal antibody K 112. Int J Cancer. 1990 Jul 15;46(1):50-5.

PubMed PMID: 2365500.

148: Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen
GA. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled
monoclonal antibodies. J Nucl Med. 2003 Aug;44(8):1271-81. PubMed PMID: 12902418.

149: van der Pas MH, van Dongen GA, Cailler F, Pèlegrin A, Meijerink WJ. Sentinel
node procedure of the sigmoid using indocyanine green: feasibility study in a
goat model. Surg Endosc. 2010 Sep;24(9):2182-7. doi: 10.1007/s00464-010-0923-3.

Epub 2010 Feb 23. PubMed PMID: 20177933; PubMed Central PMCID: PMC2939337.

150: Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM,
Verkleij AJ, van Dongen GA, van Bergen en Henegouwen PM. A biparatopic anti-EGFR
nanobody efficiently inhibits solid tumour growth. Int J Cancer. 2011 Oct
15;129(8):2013-24. doi: 10.1002/ijc.26145. Epub 2011 Aug 8. PubMed PMID:

21520037; PubMed Central PMCID: PMC4197845.

151: Heuveling DA, Visser GW, de Groot M, de Boer JF, Baclayon M, Roos WH, Wuite
GJ, Leemans CR, de Bree R, van Dongen GA. Nanocolloidal albumin-IRDye 800CW: a
near-infrared fluorescent tracer with optimal retention in the sentinel lymph
node. Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1161-8. doi:

10.1007/s00259-012-2080-5. Epub 2012 Feb 17. PubMed PMID: 22349719; PubMed

Central PMCID: PMC3369133.

152: Verel I, Visser GW, Boellaard R, Boerman OC, van Eerd J, Snow GB, Lammertsma
AA, van Dongen GA. Quantitative 89Zr immuno-PET for in vivo scouting of
90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med.
2003 Oct;44(10):1663-70. PubMed PMID: 14530484.

153: Hagens MH, Killestein J, Yaqub MM, van Dongen GA, Lammertsma AA, Barkhof F,
van Berckel BN. Cerebral rituximab uptake in multiple sclerosis: A
(89)Zr-immunoPET pilot study. Mult Scler. 2018 Apr;24(4):543-545. doi:

10.1177/1352458517704507. Epub 2017 Apr 26. PubMed PMID: 28443358; PubMed Central

PMCID: PMC5891689.

154: Börjesson PK, Jauw YW, Boellaard R, de Bree R, Comans EF, Roos JC,
Castelijns JA, Vosjan MJ, Kummer JA, Leemans CR, Lammertsma AA, van Dongen GA.
Performance of immuno-positron emission tomography with zirconium-89-labeled
chimeric monoclonal antibody U36 in the detection of lymph node metastases in
head and neck cancer patients. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2133-40.

PubMed PMID: 16609026.

155: Vosjan MJ, Vercammen J, Kolkman JA, Stigter-van Walsum M, Revets H, van
Dongen GA. Nanobodies targeting the hepatocyte growth factor: potential new drugs
for molecular cancer therapy. Mol Cancer Ther. 2012 Apr;11(4):1017-25. doi:

10.1158/1535-7163.MC11089T1. Epub 2012 Feb 7. PubMed PMID: 22319202.

156: Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR,
Giaccone G, Albano R, Comoglio PM, van Dongen GA. Quantitative PET imaging of
Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody
DN30. Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67. doi:

10.1007/s00259-008-0774-5. Epub 2008 May 20. PubMed PMID: 18491091.

157: Sijbrandi NJ, Merkul E, Muns JA, Waalboer DC, Adamzek K, Bolijn M,
Montserrat V, Somsen GW, Haselberg R, Steverink PJ, Houthoff HJ, van Dongen GA. A
Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal
and Auristatin F-Conjugated Trastuzumab. Cancer Res. 2017 Jan 15;77(2):257-267.

doi: 10.1158/0008-5472.CA16190N0. Epub 2016 Nov 21. PubMed PMID: 27872093.

158: Lambin P, Petit SF, Aerts HJ, van Elmpt WJ, Oberije CJ, Starmans MH, van
Stiphout RG, van Dongen GA, Muylle K, Flamen P, Dekker AL, De Ruysscher D. The
ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting

intra-tumour and intra-organ heterogeneity for advanced treatment of non-small
cell lung cancer. Radiother Oncol. 2010 Aug;96(2):145-52. doi:

10.1016/j.radonc.2010.07.001. Epub 2010 Jul 19. PubMed PMID: 20647155.

159: de Bree R, Roos JC, Verel I, van Dongen GA, Snow GB. Radioimmunodiagnosis of
lymph node metastases in head and neck cancer. Oral Dis. 2003 Sep;9(5):241-8.

PubMed PMID: 14628891.

160: Gerretsen M, Quak JJ, Brakenhoff RH, Snow GB, van Dongen GA. The feasibility
of radioimmunotherapy of head and neck cancer. Eur J Cancer B Oral Oncol.
1994;30B(2):82-7. PubMed PMID: 8032305.

161: Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns
JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR, van Dongen GA. Safety and
biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1
in head and neck cancer patients. Clin Cancer Res. 2000 Aug;6(8):3046-55. PubMed

PMID: 10955783.

162: Braakhuis BJ, Laarman DA, Nauta JJ, van Walsum M, van Dongen GA, Snow GB.
Transplantability of human head and neck squamous cell carcinomas in athymic nude
mice. Arch Otolaryngol Head Neck Surg. 1989 Sep;115(9):1076-8. PubMed PMID:

2765223.

163: Braakhuis BJ, van Dongen GA, Vermorken JB, Snow GB. Preclinical in vivo
activity of 2’,2’-difluorodeoxycytidine (Gemcitabine) against human head and neck
cancer. Cancer Res. 1991 Jan 1;51(1):211-4. PubMed PMID: 1988086.

164: Brown DH, Braakhuis BJ, van Dongen GA, van Walsum M, Bagnay M, Snow GB.
Activity of the folate analog 10-ethyl, 10-deaza-aminopterin (10-EdAM) against
human head and neck cancer xenografts. Anticancer Res. 1989 Nov-Dec;9(6):1549-52.

PubMed PMID: 2627109.

165: Schrijvers AH, Gerretsen M, van Walsum M, Braakhuis BJ, Quak JJ, Snow GB,
van Dongen GA. Potential for targeting head and neck squamous cell carcinoma with
monoclonal antibody K984. Cancer Immunol Immunother. 1992;34(4):252-8. PubMed

PMID: 1371426.

166: Vrouenraets MB, Visser GW, Stigter M, Oppelaar H, Snow GB, van Dongen GA.
Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing
monoclonal antibodies: improved efficacy in photodynamic therapy. Cancer Res.
2001 Mar 1;61(5):1970-5. PubMed PMID: 11280754.

167: Copper MP, Braakhuis BJ, de Vries N, van Dongen GA, Nauta JJ, Snow GB. A
panel of biomarkers of carcinogenesis of the upper aerodigestive tract as
potential intermediate endpoints in chemoprevention trials. Cancer. 1993 Feb
1;71(3):825-30. PubMed PMID: 8431864.

168: Braakhuis BJ, van Dongen GA, van Walsum M, Leyva A, Snow GB. Preclinical
antitumor activity of 5-aza-2’-deoxycytidine against human and neck cancer
xenografts ["[corrected]" not found]. Invest New Drugs. 1988 Dec;6(4):299-304. Erratum in:

Invest New Drugs 1989 Apr;7(1):117. PubMed PMID: 2466014.

169: Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P,
Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, van
Dongen GA, Merchiers P, van Rompaey P, Smit MJ. Llama-derived single variable
domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and
neck cancer cell growth in vivo. J Biol Chem. 2013 Oct 11;288(41):29562-72. doi:

10.1074/jbc.M113.498436. Epub 2013 Aug 26. PubMed PMID: 23979133; PubMed Central

PMCID: PMC3795254.

170: Quak JJ, Balm AJ, van Dongen GA, Brakkee JG, Scheper RJ, Snow GB, Meijer CJ.
A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively
expressed in stratified squamous and transitional epithelia. Am J Pathol. 1990
Jan;136(1):191-7. PubMed PMID: 2297047; PubMed Central PMCID: PMC1877446.

171: Tijink BM, De Bree R, Van Dongen GA, Leemans CR. How we do it:
Chemo-electroporation in the head and neck for otherwise untreatable patients.
Clin Otolaryngol. 2006 Oct;31(5):447-51. PubMed PMID: 17014460.

172: Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van
Dongen GA. A phase I dose escalation study with anti-CD44v6 bivatuzumab
mertansine in patients with incurable squamous cell carcinoma of the head and
neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72. PubMed PMID:

17062682.

173: Quak J, Gerretsen M, De Bree R, Brakenhof R, Van Dongen G, Snow G.
Perspectives of monoclonal antibodies for detection and treatment of head and
neck tumours. Anticancer Res. 1993 Nov-Dec;13(6B):2533-9. PubMed PMID: 8135493.

174: Eshel R, Zanin A, Kapon D, Sagi-Assif O, Brakenhoff R, van Dongen G, Witz
IP. Human 6Ly antigen E48(6LyD) regulates important interaction parameters
between endothelial cells and head-and-neck squamous carcinoma cells. Int J
Cancer. 2002 Apr 20;98(6):803-10. PubMed PMID: 11948455.

175: Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, Heider KH,
Stehle G, Snow GB, van Dongen GA. Safety, biodistribution, pharmacokinetics, and
immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4
(bivatuzumab) in patients with squamous cell carcinoma of the head and neck.
Cancer Immunol Immunother. 2003 Sep;52(9):576-82. PubMed PMID: 14627130.

176: Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH,
Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA. Phase I therapy study with
(186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients
with head and neck squamous cell carcinoma. Clin Cancer Res. 2003 Sep 1;9(10 Pt
2):396172SS. PubMed PMID: 14506195.

177: van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B,
Stigter-van Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G. The novel
AML stem cell associated antigen CL1L aids in discrimination between normal and
leukemic stem cells. Blood. 2007 Oct 1;110(7):2659-66. Epub 2007 Jul 3. PubMed

PMID: 17609428.

178: Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, Vosjan MJ,
Stigter-van Walsum M, Snow GB, van Dongen GA. Long-lived positron emitters
zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates
with PET. Cancer Biother Radiopharm. 2003 Aug;18(4):655-61. PubMed PMID:

14503961.

179: Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard
HJ, Leemans CR, van Dongen GA. Improved tumor targeting of anti-epidermal growth
factor receptor Nanobodies through albumin binding: taking advantage of modular
Nanobody technology. Mol Cancer Ther. 2008 Aug;7(8):2288-97. doi:

10.1158/1535-7163.MC07238T4. PubMed PMID: 18723476.

180: Geldof AA, Versteegh LRT, van Mourik JC, Rooimans MA, Arwert F, Hermsen MA,
Schadee-Eestermans IL, van Dongen GA, van der Valk P, van der Clement EHP, Lips
P, Teule GJ. Clonally related but phenotypically divergent human cancer cell
lines derived from a single follicular thyroid cancer recurrence (TT2609).
Thyroid. 2001 Oct;11(10):909-17. PubMed PMID: 11716037.

181: Brakenhoff RH, Knippels EM, van Dongen GA. Optimization and simplification
of expression cloning in eukaryotic vector/host systems. Anal Biochem. 1994 May
1;218(2):460-3. Erratum in: Anal Biochem 1994 Sep;221(2):434. PubMed PMID:

8074308.

182: Börjesson PK, Postema EJ, de Bree R, Roos JC, Leemans CR, Kairemo KJ, van
Dongen GA. Radioimmunodetection and radioimmunotherapy of head and neck cancer.
Oral Oncol. 2004 Sep;40(8):761-72. Review. PubMed PMID: 15288829.

183: Heuveling DA, de Bree R, van Dongen GA. The potential role of non-FDG-PET in
the management of head and neck cancer. Oral Oncol. 2011 Jan;47(1):2-7. doi:

10.1016/j.oraloncology.2010.10.008. Epub 2010 Nov 24. PubMed PMID: 21109481.

184: Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M,
Zardi L, van Dongen GA. Radioimmunotherapy of head and neck cancer xenografts
using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
J Nucl Med. 2006 Jul;47(7):1127-35. PubMed PMID: 16818947.

185: Dingemans KP, Pels E, van Dongen G, den Otter W. Destruction of murine
lymphoma cells by allogeneic peritoneal macrophages in vitro: influence of
antiserum. J Natl Cancer Inst. 1983 Jan;70(1):181-92. PubMed PMID: 6571913.